

Special Issue

Breast Cancer Risk and Prevention

Message from the Guest Editors

There is increasing evidence that the standard screening strategy is not effective in women at high risk for breast cancer. Several factors are known to influence the risk of breast cancer development, including genetic, reproductive, and hormonal factors.

Mammographic breast density and lifestyle are able to influence breast cancer risk. Therefore, in addition to personalized treatments that have allowed significant advances in the breast cancer cure rate, the issue of individualized risk assessment and prevention will represent the challenge. This Special Issue aims to focus on the more recent developments in breast cancer risk assessment and individualized prevention modalities, including genetic and hereditary breast cancer, population-based genomic screening, single-nucleotide polymorphism, dietary and lifestyle modifications and breast cancer risk, preventive medications, risk-reducing surgery in selected high-risk patients, and new techniques for diagnosis and screening. Original research articles and reviews are welcome.

Guest Editors

Dr. Tommaso Susini

Breast Unit, Gynecology Section, Department of Health Sciences, University of Florence, Florence, Italy

Prof. Dr. Laura Papi

Hereditary Cancer Laboratory, University of Florence, Florence, Italy

Deadline for manuscript submissions

closed (5 June 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/102034

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)